Halozyme Therapeutics, Inc. (HALO) Stock Price & News

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia

About Halozyme Therapeutics, Inc.

CEOჰელენ აი ტორლი

Employees423

Founded1998

Headquartersსან-დიეგო, კალიფორნია, ამერიკის შეერთებული შტატები

Sector-

Websitehalozyme.com

All values in USD	სექ. 2025	დეკ. 2025	მარ. 2026	ივნ. 2026
Revenue	354,26 მლნ.	451,77 მლნ.	376,71 მლნ.	481,00 მლნ.
Cost of goods sold	72,49 მლნ.	110,67 მლნ.	104,80 მლნ.	106,84 მლნ.
Cost of revenue	72,49 მლნ.	110,67 მლნ.	104,80 მლნ.	106,84 მლნ.
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	46,09 მლნ.	63,33 მლნ.	57,88 მლნ.	57,00 მლნ.
Operating expense	63,85 მლნ.	86,70 მლნ.	87,39 მლნ.	86,51 მლნ.
Total operating expenses	136,34 მლნ.	197,37 მლნ.	192,19 მლნ.	193,34 მლნ.
Operating income	217,92 მლნ.	254,40 მლნ.	184,52 მლნ.	287,65 მლნ.
Other non operating income	-	-	-	-
EBT including unusual items	218,96 მლნ.	-100,85 მლნ.	180,33 მლნ.	284,90 მლნ.
EBT excluding unusual items	218,96 მლნ.	251,58 მლნ.	180,30 მლნ.	284,90 მლნ.
Income tax expense	43,73 მლნ.	40,74 მლნ.	30,28 მლნ.	54,99 მლნ.
Effective tax rate	19,97%	-40,40%	16,79%	19,30%
Other operating expenses	-	-	-	-
Net income	175,22 მლნ.	-141,59 მლნ.	150,05 მლნ.	229,91 მლნ.
Net profit margin	49,46%	-31,34%	39,83%	47,80%
Earnings per share	1,72	-0,24	1,60	2,28
Interest and investment income	5,33 მლნ.	2,09 მლნ.	1,29 მლნ.	2,84 მლნ.
Interest expense	-4,30 მლნ.	-4,91 მლნ.	-5,51 მლნ.	-5,59 მლნ.
Net interest expenses	1,04 მლნ.	-2,82 მლნ.	-4,22 მლნ.	-2,75 მლნ.
Depreciation and amortization charges	-	-	-	-
EBITDA	236,84 მლნ.	279,08 მლნ.	215,65 მლნ.	319,12 მლნ.
Gain or loss from assets sale	-	2,62 მლნ.	-	76,00 ათ.

Finance

Ask anything